[Biotherapies for psoriasis: Options following the suspension of Raptiva?].
Aubin
F
F
Bachelez
H
H
Beani
J-C
JC
Berbis
P
P
Beylot-Barry
M
M
Descamps
V
V
Dubertret
L
L
Goujon
C
C
Jeanmougin
M
M
Le Maître
M
M
Ortonne
J-P
JP
Paul
C
C
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018845:CD11 Antigens / Q000627:therapeutic use; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018845:CD11 Antigens; C472181:efalizumab